申请人:GlaxoSmithKline Intellectual Property (No. 2) Limited
公开号:US10485814B2
公开(公告)日:2019-11-26
Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, for increasing insulin sensitivity in a subject, or to treat or prevent a skin condition.
The compounds have general formulas (I) or (II):
wherein R1 is —C(═O)—X—(C2-C18 straight chain or branched) alkyl or —C(═O)—X—(C2-C18 straight chain or branched) alkenyl; each R2 is independently selected from hydrogen, and a —C(O)—X—(C1-C18 straight chain or branched) alkyl or a —C(O)—X—(C2-C18 straight chain or branched) alkenyl; and X is a covalent bond or O.
本文提供了烟酰胺核糖苷和烟酰胺核糖苷氢化物的立体异构纯酯和碳酸酯类似物及其药物组合物和用途。烟酰胺核糖苷和烟酰胺核糖苷氢化物的立体异构纯酯和碳酸酯类似物可用于治疗因 NAD 水平升高而获益的疾病或紊乱,包括线粒体疾病或紊乱、胰岛素抵抗、代谢综合征、糖尿病、肥胖症,以提高受试者的胰岛素敏感性,或治疗或预防皮肤病。
这些化合物具有通式(I)或(II):
其中 R1 是-C(═O)-X-(C2-C18 直链或支链)烷基或-C(═O)-X-(C2-C18 直链或支链)烯基;每个 R2 独立地选自氢、-C(O)-X-(C1-C18 直链或支链)烷基或-C(O)-X-(C2-C18 直链或支链)烯基;以及 X 是共价键或 O。